NO321118B1 - Oralt trefase-befruktningshindrende middel - Google Patents

Oralt trefase-befruktningshindrende middel Download PDF

Info

Publication number: NO321118B1
Authority: NO; Norway
Prior art keywords: study; women; phase; days; bleeding
Prior art date: 1998-12-23

Application number

NO20013144A

Other languages

English (en)

Norwegian (no)

Other versions

NO20013144L (no

NO20013144D0 (no

Inventor

Gary Shangold

Arkady Rubin

David Upmalis

Original Assignee

Ortho Mcneil Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-23

Filing date

2001-06-22

Publication date

2006-03-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22349144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO321118(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-06-22 Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc

2001-06-22 Publication of NO20013144D0 publication Critical patent/NO20013144D0/no

2001-08-23 Publication of NO20013144L publication Critical patent/NO20013144L/no

2006-03-20 Publication of NO321118B1 publication Critical patent/NO321118B1/no

Links

229940121375 antifungal agent Drugs 0.000 title 1
239000003429 antifungal agent Substances 0.000 title 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 30
239000000262 estrogen Substances 0.000 claims description 30
229940011871 estrogen Drugs 0.000 claims description 29
229960000417 norgestimate Drugs 0.000 claims description 22
KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims description 21
239000003433 contraceptive agent Substances 0.000 claims description 17
239000000583 progesterone congener Substances 0.000 claims description 12
230000002254 contraceptive effect Effects 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 2
239000003826 tablet Substances 0.000 description 32
208000032843 Hemorrhage Diseases 0.000 description 27
208000034158 bleeding Diseases 0.000 description 27
230000000740 bleeding effect Effects 0.000 description 27
206010027514 Metrorrhagia Diseases 0.000 description 22
238000002360 preparation method Methods 0.000 description 19
238000011282 treatment Methods 0.000 description 18
239000003814 drug Substances 0.000 description 14
229940079593 drug Drugs 0.000 description 13
230000001788 irregular Effects 0.000 description 13
229940127234 oral contraceptive Drugs 0.000 description 13
239000003539 oral contraceptive agent Substances 0.000 description 13
230000002354 daily effect Effects 0.000 description 12
229960002568 ethinylestradiol Drugs 0.000 description 9
150000003431 steroids Chemical class 0.000 description 9
229940053934 norethindrone Drugs 0.000 description 8
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 8
239000006187 pill Substances 0.000 description 8
230000035935 pregnancy Effects 0.000 description 8
229960004976 desogestrel Drugs 0.000 description 7
RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 7
239000000902 placebo Substances 0.000 description 7
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
229940124558 contraceptive agent Drugs 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000027758 ovulation cycle Effects 0.000 description 5
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000003509 anti-fertility effect Effects 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
230000007717 exclusion Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
230000003821 menstrual periods Effects 0.000 description 4
230000005906 menstruation Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
230000000757 progestagenic effect Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000009424 thromboembolic effect Effects 0.000 description 3
201000005060 thrombophlebitis Diseases 0.000 description 3
230000002792 vascular Effects 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 2
206010061178 Genital haemorrhage Diseases 0.000 description 2
UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 2
206010073069 Hepatic cancer Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 2
206010047571 Visual impairment Diseases 0.000 description 2
239000001961 anticonvulsive agent Substances 0.000 description 2
229940125717 barbiturate Drugs 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000008298 dragée Substances 0.000 description 2
229940000406 drug candidate Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 2
229960002199 etretinate Drugs 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 2
229960005352 gestodene Drugs 0.000 description 2
230000036449 good health Effects 0.000 description 2
DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 2
229960002867 griseofulvin Drugs 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229960005280 isotretinoin Drugs 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
230000002175 menstrual effect Effects 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
230000008729 neurovascular lesion Effects 0.000 description 2
229940007688 norgestimate and ethinylestradiol Drugs 0.000 description 2
238000009597 pregnancy test Methods 0.000 description 2
229960001225 rifampicin Drugs 0.000 description 2
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
WNSDZLZVSSOOCA-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WNSDZLZVSSOOCA-WOMZHKBXSA-N 0.000 description 1
NAPPWIFDUAHTRY-XYDRQXHOSA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 NAPPWIFDUAHTRY-XYDRQXHOSA-N 0.000 description 1
JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010008263 Cervical dysplasia Diseases 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
239000004129 EU approved improving agent Substances 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
229940127463 Enzyme Inducers Drugs 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108700023863 Gene Components Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010023129 Jaundice cholestatic Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
201000005267 Obstructive Jaundice Diseases 0.000 description 1
SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
241000882890 Renova Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
208000024799 Thyroid disease Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000035432 Unintended pregnancy Diseases 0.000 description 1
206010046788 Uterine haemorrhage Diseases 0.000 description 1
206010046910 Vaginal haemorrhage Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
208000024776 abnormal vaginal bleeding Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
230000003579 anti-obesity Effects 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000002519 antifouling agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000013502 data validation Methods 0.000 description 1
230000006735 deficit Effects 0.000 description 1
229940063223 depo-provera Drugs 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003687 estradiol congener Substances 0.000 description 1
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
229960001348 estriol Drugs 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000003777 experimental drug Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000013003 healing agent Substances 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000009533 lab test Methods 0.000 description 1
230000003908 liver function Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
210000004914 menses Anatomy 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003217 oral combined contraceptive Substances 0.000 description 1
238000009258 post-therapy Methods 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229940059527 renova Drugs 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20013144A 1998-12-23 2001-06-22 Oralt trefase-befruktningshindrende middel NO321118B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11339498P	1998-12-23	1998-12-23
PCT/US1999/029129 WO2000038691A1 (en)	1998-12-23	1999-12-08	Triphasic oral contraceptive

Publications (3)

Publication Number	Publication Date
NO20013144D0 NO20013144D0 (no)	2001-06-22
NO20013144L NO20013144L (no)	2001-08-23
NO321118B1 true NO321118B1 (no)	2006-03-20

Family

ID=22349144

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20013144A NO321118B1 (no)	1998-12-23	2001-06-22	Oralt trefase-befruktningshindrende middel

Country Status (26)

Country	Link
US (2)	US6214815B1 (pl)
EP (1)	EP1140109B1 (pl)
JP (1)	JP2002533398A (pl)
KR (1)	KR100669165B1 (pl)
CN (1)	CN100408040C (pl)
AR (1)	AR028809A1 (pl)
AT (1)	ATE318605T1 (pl)
AU (1)	AU765153B2 (pl)
BR (1)	BR9916579A (pl)
CA (1)	CA2356747C (pl)
CY (1)	CY1105276T1 (pl)
CZ (1)	CZ302568B6 (pl)
DE (1)	DE69930157T2 (pl)
DK (1)	DK1140109T3 (pl)
ES (1)	ES2259481T3 (pl)
HU (1)	HU229251B1 (pl)
MX (1)	MXPA01006533A (pl)
NO (1)	NO321118B1 (pl)
NZ (1)	NZ512404A (pl)
PL (1)	PL196715B1 (pl)
PT (1)	PT1140109E (pl)
RU (1)	RU2225207C2 (pl)
SK (1)	SK287931B6 (pl)
TR (1)	TR200101826T2 (pl)
WO (1)	WO2000038691A1 (pl)
ZA (1)	ZA200106006B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5898032A (en)	1997-06-23	1999-04-27	Medical College Of Hampton Roads	Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
HUP9900213A1 (hu) *	1999-02-01	2000-12-28	Gábor Bogye	Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére
US20060281723A1 (en) *	1999-04-16	2006-12-14	Kafrissen Michael E	Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
EP1260225A1 (en) *	2001-05-18	2002-11-27	Pantarhei Bioscience B.V.	A pharmaceutical composition for use in hormone replacement therapy
DE60217324T2 (de) *	2001-05-18	2007-04-26	Pantarhei Bioscience B.V.	Pharmazeutische zusammensetzung für die hormonersatztherapie
US7732430B2 (en) *	2001-05-23	2010-06-08	Pantarhei Bioscience B.V.	Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
CA2448271A1 (en) *	2001-05-23	2002-11-28	Panterhei Bioscience B.V.	Means and method for hormonal contraception
EP1390041B1 (en) *	2001-05-23	2009-11-25	Pantarhei Bioscience B.V.	Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
ATE347365T1 (de) *	2001-11-15	2006-12-15	Pantarhei Bioscience Bv	Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
MXPA04005445A (es)	2001-12-05	2005-03-23	Barr Lab Inc	Anticonceptivos orales para prevenir el embarazo y disminuir la sintomatologia premenstrual.
AU2003274946A1 (en) *	2002-06-11	2003-12-22	Pantarhei Bioscience B.V.	Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
CA2489270C (en) *	2002-06-11	2012-08-07	Pantarhei Bioscience B.V.	A method of treating human skin and a skin care composition for use in such a method
US9034854B2 (en)	2002-07-12	2015-05-19	Pantarhei Bioscience B.V.	Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
JP2004140323A (ja) *	2002-08-20	2004-05-13	Sharp Corp	半導体レーザ装置およびその製造方法
US8987240B2 (en)	2002-10-23	2015-03-24	Pantarhei Bioscience B.V.	Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
JP2006525358A (ja)	2003-05-02	2006-11-09	ドゥラメドファーマシューティカルズ，インコーポレイテッド	長期周期避妊養生法を利用するホルモン治療の方法
NZ585546A (en) *	2003-07-16	2011-10-28	Teva Womens Health Inc	Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
JP2007507534A (ja) *	2003-10-01	2007-03-29	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	持続的三相避妊方法
DE102004026671A1 (de)	2004-05-28	2005-12-15	Grünenthal GmbH	Darreichungsform zur hormonalen Kontrazeption
MX2007004120A (es) *	2004-10-07	2007-06-15	Duramed Pharmaceuticals Inc	Metodos de tratamiento hormonal utilizando regimentes de ciclo prolongado de dosis ascendente.
US20070111975A1 (en)	2004-10-07	2007-05-17	Duramed Pharmaceuticals, Inc.	Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070077269A1 (en) *	2005-10-04	2007-04-05	Woodward John R	Method of birth control and hormone regulation
US20070254025A1 (en) *	2006-04-27	2007-11-01	Cronk Peter J	Oral contraceptive and acne medication combination and treatment of acne with reduced side effects
US20070254858A1 (en) *	2006-04-27	2007-11-01	Cronk Peter J	Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
CN101489563A (zh) *	2006-07-06	2009-07-22	拜耳先灵医药股份有限公司	用于避孕和预防先天性畸形风险的药物制剂
CN101583363B (zh) *	2007-01-08	2013-08-21	潘塔希生物科学股份有限公司	治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒
DE102007011486A1 (de) *	2007-03-07	2008-09-11	Grünenthal GmbH	Arzneimittel umfassend wenigstens ein Gestagen
US20100178323A1 (en)	2007-07-10	2010-07-15	Agis Kydonieus	Dermal Delivery Device
CA2740005C (en)	2008-10-08	2016-11-01	Agile Therapeutics, Inc.	Transdermal delivery
CA2740004A1 (en)	2008-10-08	2010-04-15	Agile Therapeutics, Inc.	Transdermal delivery
EP2343963B1 (en)	2008-10-08	2019-04-10	Agile Therapeutics, Inc.	Transdermal delivery
WO2010111488A1 (en)	2009-03-27	2010-09-30	Agile Therapeutics, Inc.	Transdermal delivery
US8951996B2 (en)	2011-07-28	2015-02-10	Lipocine Inc.	17-hydroxyprogesterone ester-containing oral compositions and related methods
ES3005883T3 (en)	2015-06-22	2025-03-17	Lipocine Inc	17-hydroxyprogesterone ester-containing oral compositions and related methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3568828A (en)	1967-03-01	1971-03-09	Squibb & Sons Inc	Modified sequential oral contraceptive
US3836651A (en)	1972-02-22	1974-09-17	Biolog Concepts Inc	Novel oral contraceptive combination
DE2310963A1 (de)	1972-04-14	1974-09-05	Schering Ag	Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten
US3969502A (en)	1972-04-14	1976-07-13	Schering Aktiengesellschaft	Method for contraception by the administration of sequential contraceptive preparations
US3932635A (en)	1972-04-24	1976-01-13	Syntex Corporation	Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
DE2365103C3 (de)	1973-12-21	1980-08-28	Schering Ag, 1000 Berlin Und 4619 Bergkamen	V erwendung von Hormonen zur Kontrazeption
US4291028A (en)	1977-12-30	1981-09-22	Nichols Vorys	Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
NL8001593A (nl)	1980-03-18	1981-10-16	Akzo Nv	Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4390531A (en)	1981-08-10	1983-06-28	Syntex Pharmaceuticals International Ltd.	Method of contraception using peak progestogen dosage
US4921843A (en)	1988-10-20	1990-05-01	Pasquale Samuel A	Contraception system and method
USRE35724E (en)	1982-04-28	1998-02-03	Bio-Technology General Corp.	Contraception system and method
US4544554A (en)	1983-09-26	1985-10-01	Ortho Pharmaceutical Corporation	Triphasic oral contraceptive
US4628051A (en)	1983-09-26	1986-12-09	Ortho Pharmaceutical Corporation	Triphasic oral contraceptive
US4616006A (en)	1983-09-26	1986-10-07	Ortho Pharmaceutical Corporation	Triphasic oral contraceptive
US4530839A (en)	1983-09-26	1985-07-23	Ortho Pharmaceutical Corporation	Triphasic oral contraceptive
US4962098A (en)	1987-06-15	1990-10-09	Warner-Lambert Company	Graduated estrogen contraceptive
US5023084A (en)	1986-12-29	1991-06-11	Rutgers, The State University Of New Jersey	Transdermal estrogen/progestin dosage unit, system and process
US5276022A (en)	1987-09-24	1994-01-04	Jencap Research Ltd.	Hormone preparation and method
US4948593A (en)	1989-05-15	1990-08-14	Alza Corporation	Osmotic dosage form comprising an estrogen and a progestogen
IE71203B1 (en) *	1990-12-13	1997-02-12	Akzo Nv	Low estrogen oral contraceptives
IE62665B1 (en) *	1990-12-17	1995-02-22	Akzo Nv	Contraceptive regimen
US5453279A (en)	1992-04-21	1995-09-26	Tbs Laboratories, Inc.	Enhancing transdermal absorption compositions; transdermal dosage form; and process
US5759577A (en) *	1995-01-17	1998-06-02	American Home Products Corporation	Controlled release of steroids from sugar coatings
DE19513662A1 (de) *	1995-04-08	1996-10-10	Schering Ag	Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) *	1995-06-28	1997-01-02	Schering Ag	Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5747480A (en)	1996-05-08	1998-05-05	American Home Products Corporation	Oral contraceptive

1999
- 1999-06-09 US US09/328,764 patent/US6214815B1/en not_active Expired - Lifetime
- 1999-12-08 AT AT99963049T patent/ATE318605T1/de active
- 1999-12-08 DK DK99963049T patent/DK1140109T3/da active
- 1999-12-08 PL PL349629A patent/PL196715B1/pl unknown
- 1999-12-08 KR KR1020017007809A patent/KR100669165B1/ko not_active Expired - Lifetime
- 1999-12-08 EP EP99963049A patent/EP1140109B1/en not_active Expired - Lifetime
- 1999-12-08 CA CA002356747A patent/CA2356747C/en not_active Expired - Fee Related
- 1999-12-08 CN CNB998161578A patent/CN100408040C/zh not_active Expired - Lifetime
- 1999-12-08 TR TR2001/01826T patent/TR200101826T2/xx unknown
- 1999-12-08 DE DE69930157T patent/DE69930157T2/de not_active Expired - Lifetime
- 1999-12-08 JP JP2000590643A patent/JP2002533398A/ja active Pending
- 1999-12-08 SK SK887-2001A patent/SK287931B6/sk not_active IP Right Cessation
- 1999-12-08 ES ES99963049T patent/ES2259481T3/es not_active Expired - Lifetime
- 1999-12-08 CZ CZ20012184A patent/CZ302568B6/cs not_active IP Right Cessation
- 1999-12-08 AU AU19365/00A patent/AU765153B2/en not_active Expired
- 1999-12-08 PT PT99963049T patent/PT1140109E/pt unknown
- 1999-12-08 BR BR9916579-1A patent/BR9916579A/pt not_active Application Discontinuation
- 1999-12-08 NZ NZ512404A patent/NZ512404A/en not_active IP Right Cessation
- 1999-12-08 HU HU0104680A patent/HU229251B1/hu unknown
- 1999-12-08 RU RU2001117204/15A patent/RU2225207C2/ru active
- 1999-12-08 MX MXPA01006533A patent/MXPA01006533A/es active IP Right Grant
- 1999-12-08 WO PCT/US1999/029129 patent/WO2000038691A1/en not_active Ceased
- 1999-12-22 AR ARP990106694A patent/AR028809A1/es unknown
2001
- 2001-02-13 US US09/782,420 patent/US20010044429A1/en not_active Abandoned
- 2001-06-22 NO NO20013144A patent/NO321118B1/no not_active IP Right Cessation
- 2001-07-20 ZA ZA200106006A patent/ZA200106006B/en unknown
2006
- 2006-05-17 CY CY20061100638T patent/CY1105276T1/el unknown

Also Published As

Publication number	Publication date
MXPA01006533A (es)	2002-06-04
US20010044429A1 (en)	2001-11-22
CA2356747C (en)	2005-09-27
EP1140109A1 (en)	2001-10-10
AU1936500A (en)	2000-07-31
JP2002533398A (ja)	2002-10-08
HUP0104680A2 (hu)	2002-04-29
CZ302568B6 (cs)	2011-07-13
NO20013144L (no)	2001-08-23
CA2356747A1 (en)	2000-07-06
CY1105276T1 (el)	2010-03-03
CN100408040C (zh)	2008-08-06
NO20013144D0 (no)	2001-06-22
DE69930157D1 (de)	2006-04-27
TR200101826T2 (tr)	2001-12-21
AU765153B2 (en)	2003-09-11
WO2000038691A1 (en)	2000-07-06
AR028809A1 (es)	2003-05-28
NZ512404A (en)	2003-08-29
BR9916579A (pt)	2001-10-02
KR20010081087A (ko)	2001-08-25
KR100669165B1 (ko)	2007-01-17
EP1140109B1 (en)	2006-03-01
RU2225207C2 (ru)	2004-03-10
PL196715B1 (pl)	2008-01-31
DK1140109T3 (da)	2006-05-15
ES2259481T3 (es)	2006-10-01
ZA200106006B (en)	2002-10-21
US6214815B1 (en)	2001-04-10
ATE318605T1 (de)	2006-03-15
DE69930157T2 (de)	2006-08-31
HUP0104680A3 (en)	2002-06-28
SK287931B6 (sk)	2012-04-03
CN1334734A (zh)	2002-02-06
HU229251B1 (en)	2013-10-28
SK8872001A3 (en)	2002-03-05
CZ20012184A3 (cs)	2003-01-15
PT1140109E (pt)	2006-05-31

Legal Events

Date	Code	Title	Description
2020-01-13	MK1K	Patent expired

Publication	Publication Date	Title
RU2225207C2 (ru)	2004-03-10	Трехфазный пероральный контрацептив
ÅKerlund et al.	1993	Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinyl oestradiol
Koopersmith et al.	1996	The use of misoprostol for termination of early pregnancy
JPH08510993A (ja)	1996-11-19	ホルモン補充方法
Verhoeven et al.	2004	The contraceptive vaginal ring, NuvaRing®, and antimycotic co-medication
Ornstein et al.	2006	Hormonal contraception in adolescents: special considerations
Mircette™ Study Group	1998	An open-label, multicenter, noncomparative safety and efficacy study of Mircette™, a low-dose estrogen-progestin oral contraceptive
JPS60100520A (ja)	1985-06-04	周閉経期、閉経期および閉経期後の障害をホルモン的に治療する医薬品組成物
EP3164134A1 (en)	2017-05-10	Method for providing regular contraception
US20050038006A1 (en)	2005-02-17	Triphasic oral contraceptive
CA2623024C (en)	2012-03-06	Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives
Dunson et al.	1993	A multicenter comparative trial of triphasic and monophasic, low-dose combined oral contraceptives
Takkar et al.	1999	Early abortion by mifepristone (RU 486) followed by vaginal gel (meteneprost) versus oral (misoprostol) prostaglandin
Start	0	FULL PRESCRIBING INFORMATION: CONTENTS
Start	0	1 INDICATIONS AND USAGE
AU2024343605A1 (en)	2026-02-26	Estetrol for use in the treatment of female sexual arousal disorder
Start	0	FDA Label for Drospirenone And Ethinyl Estradiol
Label	0	FDA Label for Officella
Files et al.	0	Label: GIANVI-drospirenone and ethinyl estradiol kit
Label	0	FDA Label for Yaz
Label	0	FDA Label for Loryna
Label	0	FDA Label for Gianvi